U.S. Bill Aims To Streamline Combo Product Regulation
This article was originally published in PharmAsia News
Executive Summary
In a move that could affect applicants from Asia and elsewhere, a U.S. Senate bill aims to streamline device/drug combination registrations at the FDA by letting the agency rely on prior premarket approvals and approved drug findings to help support new product approvals, among other reforms.
You may also be interested in...
White House To Deliver 25 Million Face Masks To Low-Income Americans
The White House will be spending $86m to provide tens of millions of coronavirus masks to poorer American households.
HHS Secretary Nominee Becerra Commits To Telehealth Expansion, Procedure Price Transparency
At two recent confirmation hearings, HHS secretary nominee Xavier Becerra promised Senators he would help expand telehealth and procedure price transparency.
US Medicare Agency Makes It Easier For Texas Suppliers To Replace DME Lost To Winter Storms
Durable medical equipment suppliers get temporary HHS and CMS waivers to help Texas Medicare and Medicaid beneficiaries due to the state’s winter storm.